@article{44d684d8a2904da6996c4bcb8f866fac,
title = "Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3",
keywords = "Aficamten, REDWOOD-HCM, obstructive hypertrophic cardiomyopathy, refractory obstructive hypertrophic cardiomyopathy",
author = "{REDWOOD-HCM INVESTIGATORS} and OWENS, {ANJALI T.} and AHMAD MASRI and ABRAHAM, {THEODORE P.} and LUBNA CHOUDHURY and FLORIAN RADER and SYMANSKI, {JOHN D.} and TURER, {ASLAN T.} and WONG, {TIMOTHY C.} and ALBREE TOWER-RADER and COATS, {CAROLINE J.} and FIFER, {MICHAEL A.} and IACOPO OLIVOTTO and SOLOMON, {SCOTT D.} and WATKINS, {HUGH C.} and HEITNER, {STEPHEN B.} and JACOBY, {DANIEL L.} and STUART KUPFER and MALIK, {FADY I.} and MENG, {L. I.S.A.} and REGINA SOHN and WOHLTMAN, {A. M.Y.} and MARON, {MARTIN S.}",
note = "Funding Information: The REDWOOD-HCM trial was funded by Cytokinetics. The study was designed and conducted by the steering committee, which included representatives of the sponsor. Cytokinetics was also responsible for site monitoring and data management as well as data analysis. Interpretation of the data and preparation of the manuscript were carried out by the steering committee, including representatives of Cytokinetics. Review and approval of the manuscript, as well as the decision to submit the manuscript for publication, were conducted by all authors, including representatives of Cytokinetics. Cytokinetics had no veto of the right to publish or control over to which journal the article was submitted. ",
year = "2023",
month = nov,
doi = "10.1016/j.cardfail.2023.07.003",
language = "English (US)",
volume = "29",
pages = "1576--1582",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "11",
}